CDC staff 'blindsided' as child vaccine schedule unilaterally overhauled
Comments
2 часа назад @ unmc.eduEngitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing. The financing was provided by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital […]
The post London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies appeared first on EU-Startups.
1 day, 18 hours назад @ eu-startups.comDark Blue Therapeutics, a British discovery and development BioTech company innovating the next generation of precision oncology medicines, has been acquired by US-based global BioTech company Amgen, in a transaction valued at up to €718 million ($840 million). Dark Blue’s lead candidate DBT 3757 is a first-in-class therapy in IND-enabling studies for leukemia, with the […]
The post Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme appeared first on EU-Startups.
2 days, 17 hours назад @ eu-startups.com